Pharmaceutical Industry News | The Pharmaletter
WEBAug 20, 2024 · Jazz Pharma raises $850 million through note offering. Jazz Pharmaceuticals (Nasdaq: JAZZ) is to raise $850 million with the pricing of exchangeable senior notes, due 2030. 4 September 2024.
Special Reports - The Pharma Letter
WEBJun 17, 2020 · Our latest Special Report is a review of key factors impeding progress of US biosimilar adoption written by Helen Ji, an associate at Schiff Hardin LLP, Rekha Hanu, executive director and chief IP counsel at Akorn Pharmaceuticals and Christine Simmon, SVP for policy and strategic alliances at the Association for Accessible Medicines. 4 …
Pharma, Biotech and Generics Industry News | The Pharmaletter
WEBSep 3, 2024 · Generics. 7 August 2024 US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. Belgium’s largest drugmaker UCB announced a strategic divestment …
Humanwell Healthcare and PuraCap to acquire Epic Pharma
WEBGenerics. 8 April 2016. China-based Humanwell Healthcare Group and PuraCap Pharmaceutical have entered into a definitive agreement to acquire 100% of privately-held US generic drugs marker Epic Pharma. The acquisition, which involves a payment of $550 million, will further establish Humanwell and PuraCap in …
Guy Martin - The Pharmaletter
WEBSep 11, 2024 · Guy Martin. Reporter The Pharma Letter. Guy Martin has been a journalist since 2008. He writes about all areas of pharma and biotech, and related business news. He has a special interest in emerging technologies leading to the development of personalized medicines, along with the changes this will bring to the pharmaceutical industry and beyond.
About The Pharma Letter | The Pharmaletter
WEBSep 8, 2024 · The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the company draws from a network of foreign correspondents, with healthcare journalists around the world providing insight on local markets.
Innoskel | Biotechnology - The Pharmaletter
WEBInnoSkel is developing treatment options for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which is spondyloepiphyseal dysplasia congenita, the second leading cause of dwarfism worldwide.
Positive top-line Phase II results for Soterios’ STS-01 in alopecia
WEB31 May 2024. Privately-held UK clinical-stage firm Soterios Pharma has announced positive multi-dose Phase II trial evaluating STS-01 as a treatment for mild/moderate alopecia areata (AA). At 24 weeks, 75.9% of patients treated with once-daily topical dosing of 1% STS-01 met the primary efficacy endpoint (achieving >30% improvement in SALT ...
Denmark's LEO Pharma initiates Picato phase-out - The Pharma …
WEBPharmaceutical. 28 October 2020. Following safety warnings on Picato (ingenol mebutate) from regulators, including the European Medicines Agency and the US Food and Drug Administration, Danish drugmaker LEO Pharma yesterday announced it was initiating a phase-out for the product, a gel for the treatment of actinic keratosis, which is expected ...
Pharma and Biotech News | The Pharmaletter
WEB2 days ago · Research shows migraine market to reach $16.4 billion by 2033. The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024. Biotechnology.